{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:59:10Z","timestamp":1775804350903,"version":"3.50.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lung cancer remains the leading cause of cancer-related deaths worldwide. With the development of targeted therapy and immunotherapy, the prognosis of patients with advanced non-small cell lung cancer has been significantly improved. However, the occurrence of comorbidities such as pulmonary fibrosis (PF) and pulmonary embolism (PE) significantly worsens the prognosis of these patients. Nintedanib is an effective antifibrotic drug, but its inhibition of vascular endothelial growth factor receptor may increase the risk of bleeding. Anticoagulant therapy is the cornerstone of PE treatment, and the combined use of nintedanib and anticoagulants may further increase the bleeding risk, which poses a clinical dilemma. At present, real-world data on the combined use of nintedanib and anticoagulants in patients with lung cancer complicated with PF and PE are scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We reported two cases of patients with advanced lung adenocarcinoma complicated with PF and PE. Case 1 was a 67-year-old male patient with left lung adenocarcinoma (cT2N2M1c IVB) complicated with idiopathic pulmonary fibrosis and acute PE. He had a history of hemoptysis after chemotherapy and was treated with nintedanib for antifibrosis before admission. After admission, nintedanib was temporarily discontinued due to the relative contraindication between anticoagulation therapy and bleeding. After the patient's condition stabilized, low-dose nintedanib was reinitiated, and the anticoagulant was switched to rivaroxaban orally after discharge. Follow-up showed no bleeding and the thrombosis disappeared. Case 2 was a 69-year-old male patient with right lung adenocarcinoma (cT4N3M1a IVA) with BRAF V600E and TP53 mutations, complicated with drug-related interstitial pneumonia and acute PE. He was treated with nintedanib combined with enoxaparin sodium. After the occurrence of mild hemoptysis, only the anticoagulant dose was adjusted without discontinuing nintedanib, and the bleeding symptoms were gradually relieved after discharge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The core contradiction in the treatment of advanced lung adenocarcinoma complicated with PF and PE is the balancing of bleeding risk between nintedanib antifibrotic treatment and anticoagulant therapy. Clinical decisions need to be based on individualized risk-benefit assessment. Individualized risk assessment and precise plan adjustment are key to improving the prognosis of these complex patients and providing practical references for similar clinical cases. Further studies are required in the future to confirm the safety of nintedanib when used in combination with anticoagulants.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1771163","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:03:54Z","timestamp":1775801034000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Nintedanib combined with anticoagulant therapy in advanced lung cancer complicated with pulmonary fibrosis and pulmonary embolism: two case reports and clinical decision-making analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiuli","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Weifang People's Hospital","place":["Weifang, Shandong, China"]},{"name":"Pharmacy Department, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[{"name":"Pharmacy Department, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenming","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Weifang People's Hospital","place":["Weifang, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baosheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Weifang Hospital of Traditional Chinese Medicine","place":["Weifang, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-025-01679-1","article-title":"Recent advances in therapeutic strategies for non-small cell lung cancer","volume":"18","author":"Su","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.19538\/j.nk2025060105","article-title":"Prevention and treatment of common complications in advanced lung cancer","volume":"45","author":"Wang","year":"2025","journal-title":"Chin J Pract Internal Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1186\/s12967-025-06514-2","article-title":"Pulmonary fibrosis: from mechanisms to therapies","volume":"23","author":"Jiang","year":"2025","journal-title":"J Transl Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40265-021-01487-0","article-title":"Nintedanib: a review in fibrotic interstitial lung diseases","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"10.6004\/jnccn.2021.7108","DOI":"10.6004\/jnccn.2021.7108","article-title":"Update on guidelines for the prevention of cancer-associated thrombosis","volume":"20","author":"Elshoury","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B8","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s40264-020-00978-5","article-title":"Anticoagulant use and bleeding risk in central European patients with idiopathic pulmonary fibrosis (IPF) treated with antifibrotic therapy: real-world data from EMPIRE","volume":"43","author":"Kolonics-Farkas","year":"2020","journal-title":"Drug Saf"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.3760\/cma.j.cn112137-20250509-01141","article-title":"Chinese Guidelines for the diagnosis, treatment, prophylaxis and management of pulmonary thromboembolism","volume":"105","year":"2025","journal-title":"Nat Med J China"},{"key":"B10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jama.2023.9844","article-title":"Prophylaxis against Pneumocystis jirovecii pneumonia in adults","volume":"330","author":"Zhou","year":"2023","journal-title":"JAMA"},{"key":"B11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3760\/cma.j.cn112152-20220412-00244","article-title":"Expert consensus on the diagnosis and treatment of anticancer drug-induced interstitial lung disease","volume":"44","year":"2022","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.3390\/biomedicines12122650","article-title":"Drug-induced pulmonary fibrosis: national database analysis","volume":"12","author":"Butranova","year":"2024","journal-title":"Biomedicines"},{"key":"B13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/14787210.2023.2153116","article-title":"Nintedanib: a review of the properties, function, and usefulness to minimize COVID-19-induced lung injury","volume":"21","author":"Hashemian","year":"2023","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"7849","DOI":"10.3390\/ijms24097849","article-title":"Efficacy of pirfenidone and nintedanib in interstitial lung diseases other than idiopathic pulmonary fibrosis: a systematic review","volume":"24","author":"Amati","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12890-021-01783-1","article-title":"Kamil H. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis","volume":"21","author":"Finnerty","year":"2021","journal-title":"BMC Pulm Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"103186","DOI":"10.1016\/j.critrevonc.2020.103186","article-title":"Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: a network meta-analysis","volume":"157","author":"Das","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1097\/HJH.0b013e3283309b59","article-title":"Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects","volume":"27","author":"Kappers","year":"2009","journal-title":"J Hypertens"},{"key":"B18","doi-asserted-by":"publisher","first-page":"107983","DOI":"10.1016\/j.phrs.2025.107983","article-title":"Vascular endothelial cells and angiogenesis","volume":"221","author":"Roskoski","year":"2025","journal-title":"Pharmacol Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/14740338.2020.1691167","article-title":"Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?","volume":"19","author":"Furuya-Kanamori","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e000397","DOI":"10.1136\/bmjresp-2018-000397","article-title":"Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials","volume":"6","author":"Lancaster","year":"2019","journal-title":"BMJ Open Respir Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1007\/s12325-024-03023-4","article-title":"Safety and tolerability of nintedanib in patients with fibrosing interstitial lung diseases: post-marketing data","volume":"41","author":"Chaudhuri","year":"2024","journal-title":"Adv Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S2213-2600(18)30339-4","article-title":"Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON","volume":"7","author":"Crestani","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.1111\/bcp.14861","article-title":"Aortic intramural haematoma associated with the use of nintedanib","volume":"87","author":"Willems","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1561440","DOI":"10.3389\/fonc.2025.1561440","article-title":"Acute thrombocytopenia and fibrinogen reduction occurring after nintedanib treatment for immune checkpoint inhibitor-related pneumonia: a case report","volume":"15","author":"Zheng","year":"2025","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1186\/s13256-024-04790-y","article-title":"Asymptomatic thrombocytopenia after nintedanib initiation in a patient with progressive pulmonary fibrosis: a case report and review of literature","volume":"18","author":"Zhang","year":"2024","journal-title":"J J Med Case Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3390\/medicina59050999","article-title":"Drug-induced thrombocytopenia due to nintedanib during treatment of idiopathic pulmonary fibrosis","volume":"59","author":"Dumic","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3390\/ph16020307","article-title":"Nintedanib in idiopathic pulmonary fibrosis: tolerability and safety in a real life experience in a single centre in patients also treated with oral anticoagulant therapy","volume":"16","author":"Ruaro","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3390\/ijms22010282","article-title":"The interactions of nintedanib and oral anticoagulants-molecular mechanisms and clinical implications","volume":"22","author":"Grze\u015bk","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000495046","article-title":"Nintedanib in idiopathic pulmonary fibrosis: practical management recommendations for potential adverse events","volume":"97","author":"Bendstrup","year":"2019","journal-title":"Respiration"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1183\/13993003.00280-2016","article-title":"Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment","volume":"48","author":"Klok","year":"2016","journal-title":"Eur Respir J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1016\/j.chest.2021.06.048","article-title":"An original risk score to predict early major bleeding in acute pulmonary embolism: the syncope, anemia, renal dysfunction (PE-SARD) bleeding score","volume":"160","author":"Chopard","year":"2021","journal-title":"Chest"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1093\/europace\/euac020","article-title":"Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: a position paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society","volume":"24","author":"Gorog","year":"2022","journal-title":"Europace"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis","volume":"300","author":"Nalluri","year":"2008","journal-title":"JAMA"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.3390\/cancers15153893","article-title":"Cancer-associated thrombosis on bevacizumab: risk of recurrence and bleeding when bevacizumab is stopped or continued","volume":"15","author":"Mayenga","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1771163\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:03:57Z","timestamp":1775801037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1771163\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":35,"alternative-id":["10.3389\/fcvm.2026.1771163"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1771163","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"article-number":"1771163"}}